Status:
COMPLETED
Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia
Lead Sponsor:
Shaheed Zulfiqar Ali Bhutto Medical University
Conditions:
Fibromyalgia
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modalit...
Detailed Description
180 drug naive patients with newly diagnosed fibromyalga according to the modified ACR 2016 criteria shall be enrolled by consecutive sampling after taking written informed consent. Baseline severity ...
Eligibility Criteria
Inclusion
- Drug Naive patients
- Newly diagnosed with FIbromyalgia according to Modified ACR 2016 criteria
Exclusion
- Concomitant depression/bipolar disorder or any other documented psychiatric illness
- Autoimmune disorders (SLE, RA)
- Peripheral Neuropathic pain due to any cause
- Uncontrolled hypertension
- Impaired renal or hepatic functions (on Lab assay)
- Chronic infections (e.g.Tuberculosis)
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 26 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03487211
Start Date
April 9 2018
End Date
February 26 2020
Last Update
February 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pakistan Institute of Medical Sciences
Islamabad, Islamabad, Pakistan, 44000